Pattern of sumatriptan use and overuse in general practice.
OBJECTIVE
To investigate the frequency of use and misuse of sumatriptan, and to explore the characteristics of patients reporting overuse.


METHODS
A postmarketing cohort study on adverse reactions to sumatriptan, performed with the assistance of drug-dispensing general practitioners in the Netherlands.


METHODS
Questionnaires were sent to patients on sumatriptan of drug-dispensing general practitioners in the Netherlands. Use of sumatriptan was classified into five groups: < 1, 1-10, 11-20 and 21-30 times per month and a group of patients who reported daily use of sumatriptan more than 10 times per week. Patients in the latter group were regarded as "overusers".


RESULTS
The request to the 1720 patients yielded a response rate of 1202 (70%). Of 952 (79%) of these patients, details of their sumatriptan intake were available. Most patients (718, 75%) took sumatriptan 1-10 times each month. However, 36 patients (4%, 95% CI 2.8-5.2%) took sumatriptan daily or more than 10 times each week. The group with the highest intake consisted mainly of males, and many patients who reported a poor efficacy of sumatriptan. Age was not related to use of sumatriptan.


CONCLUSIONS
A small group of patients (4%) used sumatriptan too often. A high intake was associated with both male gender and a reported poor efficacy of sumatriptan, but not with age, reported adverse reactions, or headache attributed to sumatriptan. It is important to explain to patients that sumatriptan is only for the treatment of acute attacks, and not for prophylactic use. Drug consumption patterns have to be evaluated, in particular in patients who report low efficacy of sumatriptan.
Ottervanger
J P
JP
Netherlands Centre for Monitoring of Adverse Reactions to Drugs, Rijswijk, The Netherlands.
Valkenburg
H A
HA
Grobbee
D E
DE
Stricker
B H
BH
D000284:Administration, Oral; D000328:Adult; D003027:Cluster Headache / Q000188:drug therapy; D015331:Cohort Studies; D004363:Drug Utilization; D005194:Family Practice; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy; D009426:Netherlands; D010349:Patient Compliance; D012646:Self Administration; D018170:Sumatriptan / Q000008:administration & dosage* / Q000009:adverse effects
D018170:Sumatriptan